... به پایگاه اطلاع رسانی فصلنامه دانش و تندرستی خوش آمدید            ... به پایگاه اطلاع رسانی فصلنامه دانش و تندرستی خوش آمدید  
  صفحه اصلی  |   تماس با ما  |   آرشیو مجله  |   نقشه سایت  |   عضویت  |   ارسال مقاله  |   پیگیری مقاله  |   English تاريخ: 4/7/1396
نام كاربري
كلمه ورود
درخواست عضویت
کلمه ورود را فراموش کرده ام

صاحب امتیاز:
دانشگاه علوم پزشکی وخدمات بهداشتی - درمانی شاهرود
مدیر مسئول: دکتر ‌جواد نوریان
سردبیر: دکتر سهراب حاجی‌‌‌زاده
مدیر اجرایی: احمد خسروی

آدرس: شاهرود- میدان هفتم تیر- ساختمان مرکزی دانشگاه علوم پزشکی شاهرود– معاونت آموزشی، پژوهشی– دفتر مجله دانش و تندرستی
تلفن: 3394111-0273
نمابر: 3394800-0273
پست الکترونیک: m_jdanesh@yahoo.com

صفحه نخست :: صفحه قبل

جستجوی پیشرفته جدید

Journal Title: زمستان 1390
Article title: The Effect of Adding Low dose Daclizumab to Renal Transplantation Standard Protocol on Reduction the Risk of Kidney Rejection in Renal Allograft Recipients

Article File:  متن کامل (PDF) 255 Kb 
Page From: 1 To: 4      
Visit: 2240

Article abstract:
Introduction: Transplantation of the kidney is the choice treatment of advanced chronic renal failure. One of the most important therapeutic problems in these patients is the prevention of acute graft rejection. The purpose of this study was to investigate the efficiency of low dose Daclizumab for prevention of acute kidney graft rejection in living donor recipients. Methods: This clinical trial study was performed on 120 living donor kidney recipients who were admitted to kidney transplant ward of Kerman Afzalipour hospital. These patients were randomly assigned into two intervention and control groups. The intervention group received Cyclosporine, Mycophenolate mofetil and Prednisolone plus Daclizumab at a dose of 1mg/kg before transplantation and then two weeks later. Other 60 patients received all above drugs except Daclizumab. All patients were followed up for at least 6 months for acute rejection, rejection episode time and the rate of infectious complications. Results: The rate of acute rejection was significantly lower in the intervention group compared with the control group (6.7% vs. 18.3%; P=0.048). The six-month graft survival rate in the intervention group was 95% and in the control group it was 85% (P=0.029). There was a significant difference in 6-month graft survival between the women of the intervention and control groups (97% vs. 74%; P=0.02) but no significant difference was observed between the men in the two groups (94% and 92%). The incidence of serious infection was similar in the two groups Conclusion: The use of induction therapy with two doses of Daclizumab in living donor kidney recipients reduces the incidents of acute rejection with improving graft survival especially in women and does not result in more infectious complications

Article keyWords:
Daclizumab, Renal transplantation, Acute rejection

Article Authors:
Jalal AzmandianFirst Author
zahra shafiiFirst Authorshafii_zahra@yahoo.com
Seyyed Mojtaba SohrevardiOther Author
Faramarz FazeliOther Author
Abbas EtminanOther Author
Sara Azizi sholOther Author




بالای صفحه
صفحه اصلی  |   تماس با ما  |   آرشیو مجله  |   نقشه سایت  |   عضویت  |   ارسال مقاله  |   پیگیری مقاله

استفاده از مطالب این سایت با ذکر نام سایت مجاز می باشد   -   Copyright © 2007 2009 - Last Update 5-11-2009
Powered By www.itpco.net    www.itpco.ir
( ITPCO ) شرکت توسعه انفورماتیک ایران
تولید کننده سیستم های تخصصی مدیریت نشریات و همایش ها و مورد تائید کمیسیون نظارت بر نشریات پزشکی وزارت بهداشت درمان و آموزش پزشکی کشور